SELECT * FROM `stock_list` where symbol='J7Z' AND exchange = 'FRA' limit 0,1
SELECT * FROM `stock_list` where symbol='J7Z' AND exchange = 'FRA' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "J7Z" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 Jazz Pharmaceuticals (FRA:J7Z) Pre-Tax Income
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Pre-Tax Income

Jazz Pharmaceuticals (FRA:J7Z) Pre-Tax Income : €277 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Jazz Pharmaceuticals's pretax income for the three months ended in Dec. 2023 was €56 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was €277 Mil. Jazz Pharmaceuticals's pretax margin was 6.08%.

During the past 13 years, Jazz Pharmaceuticals's highest Pretax Margin was 35.78%. The lowest was -10.19%. And the median was 16.97%.


Jazz Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Jazz Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Pre-Tax Income Chart

Jazz Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 408.87 226.13 -99.86 -351.91 273.20

Jazz Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -320.95 51.46 75.49 93.25 56.42

Competitive Comparison of Jazz Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Jazz Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Pre-Tax Income falls into.



Jazz Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Jazz Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=547.981+-9.365+-265.415+0+5.6843418860808E-14
=273

Jazz Pharmaceuticals's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=128.836+-7.929+-64.487+0+-0.001000000000019
=56

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €277 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jazz Pharmaceuticals  (FRA:J7Z) Pre-Tax Income Explanation

Jazz Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=56.419/927.944
=6.08%

During the past 13 years, Jazz Pharmaceuticals's highest Pretax Margin was 35.78%. The lowest was -10.19%. And the median was 16.97%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jazz Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Jazz Pharmaceuticals (FRA:J7Z) Business Description

Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines